Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Research Opens Door for Monocyte-Based Cell Therapy

By Drug Discovery Trends Editor | April 19, 2016

Researchers from VIB-UGent reveal that adult circulating monocytes that get access to the macrophage niche in the liver or the lung can acquire identical tissue-specific macrophage functions and self-maintenance capacities as macrophages of embryonic origin. This paves the way towards monocyte-based cellular therapy in diseases associated with macrophage dysfunction, such as the disease known as pulmonary alveolar proteinosis. Using a mouse model for pulmonary alveolar proteinosis, the authors demonstrate that this rare disease can be cured by a single transfer of monocytes.

Elie Metchnikoff first identified macrophages in 1882 and was awarded the Nobel prize for his discovery in 1908 together with Paul Elrich. 2016 marks the centenary of the death of Elie Metchnikoff, yet we are still only scratching the surface with our understanding of these fascinating cells that, in addition to acting as sentinels of the immune system, are also essential for the day-to-day function of their organ of residence.

Until now scientists have speculated that the unique functional and self-maintenance capacities of tissue-resident macrophages are linked to their embryonic origin. This hypothesis was fueled by recent studies, showing that macrophages derived from embryonic progenitors are long-lived and self-maintaining whereas macrophages derived from adult circulating monocytes are short-lived. Validating this hypothesis experimentally has however been challenging as not only the precursors but also the tissues they colonize differ greatly.

Using unique mouse models, researchers at VIB-UGent under direction of Martin Guilliams now reveal that circulating monocytes can acquire identical tissue-specific functions and self-maintenance capacities as compared to embryonic precursors, provided that they get access to the steady state tissue-resident macrophage niches. Using a novel model allowing the specific depletion of liver-resident embryonic-derived macrophages, called Kupffer cells, Martin Guilliams and colleagues demonstrated that blood monocytes colonize the emptied Kupffer cell niche in a single wave and rapidly differentiate into macrophages that are identical to their embryonic counterparts within 2 weeks. In addition, when transferred into the lungs of mice lacking alveolar macrophages, both adult monocytes and embryonic precursors developed into identical, fully functional alveolar macrophages that self-maintained and prevented disease for up to 1 year.

Charlotte Scott (VIB/UGent): “These studies addressed the question of nature versus nurture in macrophage development. The main factor controlling the functional specialization and self-maintenance capacity of macrophages is not the nature of the macrophage precursor, but rather nurture by the tissue of residence. Each progenitor receives tissue-specific signals which endow upon them the correct macrophage profile for that specific tissue. What these signals are and which cells produce them remains unknown but these are the next exciting questions we are working on.”

Martin Guilliams (VIB/UGent): “In fact these findings would predict the existence of a restricted number of macrophage niches per tissue that would get colonized by embryonic macrophages before birth and remain inaccessible to circulating monocytes in adulthood as long as the niche is occupied. However, our data demonstrate that if we can empty these niches by depleting the resident macrophages then circulating monocytes colonize these niches rapidly and once they have, remain in these niches forever”.

Lianne van de Laar (VIB/UGent): “The fact that circulating monocytes, which – as opposed to embryonic precursors – are easily accessible by blood donation, have the capacity to engraft permanently in tissues opens the way for monocyte-based cellular therapy for diseases in which macrophages play a crucial role. We demonstrated the feasibility of this approach using a mouse model for a rare disease known as pulmonary alveolar proteinosis, as a single transfer of monocytes was able to durably prevent the development of the disease.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE